Share on StockTwits

Alimera Sciences (NASDAQ:ALIM) major shareholder L.P. Bavp sold 39,500 shares of the company’s stock on the open market in a transaction dated Thursday, September 4th. The stock was sold at an average price of $6.33, for a total transaction of $250,035.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of Alimera Sciences (NASDAQ:ALIM) traded down 3.14% on Thursday, hitting $6.17. The stock had a trading volume of 67,766 shares. Alimera Sciences has a 52-week low of $1.65 and a 52-week high of $8.44. The stock has a 50-day moving average of $5.7 and a 200-day moving average of $6.08. The company’s market cap is $249.4 million.

Alimera Sciences (NASDAQ:ALIM) last announced its earnings results on Thursday, August 7th. The company reported ($0.15) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.23) by $0.08. The company had revenue of $2.19 million for the quarter, compared to the consensus estimate of $2.70 million. During the same quarter last year, the company posted ($0.67) earnings per share. Alimera Sciences’s revenue was up 1123.5% compared to the same quarter last year. On average, analysts predict that Alimera Sciences will post $-1.19 earnings per share for the current fiscal year.

Alimera Sciences, Incis a biopharmaceutical company that develops and commercializes prescription ophthalmic pharmaceuticals.

Receive News & Ratings for Alimera Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.